The need for assessing noncancer risks for agents to which humans are routinely exposed indoors arises from the large amount of time spent indoors (i.e., employed persons spend about 60% of their time at home indoors, 30% at work indoors, and 5% in transit). Sources ofair poilutants include heating and coolig systems, combustion appliances, personal use products, furnishings, tobacco products, pesticides, biodefluents from humansand animals, and other microbial contamination such as toxins fromn molds. The purpose of this paper is to describe current dose-response a ent mhods appliable to as risk follwing exposure to indoor air uant The role ofstuture-activity riationships in hazard identification is also described.
Introduction
The need for assessing noncancer risks for agents to which humans are routinely exposed indoors arises from the large amount of time spent indoors. Ott (I) has reported that employed persons spend about 60% oftheir time at home indoors, 30% at work indoors, and 5 % in transit. Sources ofair pollutants include heating and cooling systems, combustion appliances, personal use products, furnishings, tobacco products, outside pollutants and soil gases, cleaning and maintenance products, pesticides, bioeffluents from humans and animals, and other microbial contamination such as toxins from molds (2) . Concentrations of some compounds (e.g., volatile organics) may reach concentrations 100-fold higher indoors than outdoors. The purpose ofthis paper is to describe current dose-response assessment methods applicable to assessing risk following exposure to indoor air pollutants. The role of structure-activity relationships in hazard identification is also described.
The National Research Council (3) has summarized risk assessment and its application to indoor and outdoor air pollutants and air pollution-associated health effects. Four quantitative relationship between the magnitude ofexposure and the occurrence ofhuman health effects. Exposure assessment is the determination of the extent of human exposure including evaluation of the exposure and the number of people exposed. Risk characterization is the description of the nature, and often the magnitude, of human risk, including attendant uncertainty. Essentially, risk assessment is an integration of dose-response assessment and exposure assessment. While the National Academy of Science has described the four components of risk assessment as separate entities, hazard identification and dose response may be conducted concurrently when dealing with noncancer end points. Developmental, reproductive, and neurotoxicity risk assessment guidelines combine these two components.
Current dose-response assessment methods are described here. The interim inhalation reference concentration method is expanded in greatest detail (4) . Also described are methodologies for performing dose-response assessments by modeling dose-response relationships and using the decision analytic approach (5) .
Inhalation Reference Concentration
The U.S. EPA has chosen the reference concentration (RfC) methodology to clarify aspects of risk assessment formerly covered by the acceptable daily intake (ADI). The RfC is defined as an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. The requirements for estimating an inhalation RfC are toxicity data, uncertainty factors, and possibly a modifying factor. The RfC is determined as RfC = NOAEL/(UF x MF) where NOAEL = no-observed-adverse-effect level; UF = uncertainty factor; and MF = modifying factor.
The operating assumption in RfC development is that a dose threshold exists at or above which an adverse effect will be evoked in an organism if exposure occurs throughout a lifetime. This assumption is well-founded for many compounds that have defined toxicity mechanisms (6) , though inconsistencies in subpopulation thresholds may make the assumption invalid when considering different populations (7) . The NOAEL is the first basis for evaluating the RfC. It is derived from toxicity data in which a critical effect having a dose-response relationship is identified. The The UFs are generally order-of-magnitude values based on the chosen critical effect and represent the second basis for the scientific evaluation ofthe RfC. A 10-fold uncertainty factor is invoked to account for the variation in sensitivity among human subpopulations. Extrapolation of animal data to average, healthy humans also invokes a 10-fold uncertainty factor. When less than chronic NOAELs are used as a basis for the RfC, a 10-fold uncertainty factor is used (unless the critical effect is developmental or reproductive because a single exposure may be sufficient to produce an adverse effect). When the RfC basis is a lowestobserved-adverse-effect level (LOAEL) rather than a NOAEL, a 10-fold uncertainty factor is used. Ifthe database is incomplete (e.g., only a single animal study is available), a 10-fold uncertainty factor is used. The RfC may be altered with a modifying factor (MF) from 1 to 10 if the critical study has scientific weaknesses or uncertainties or 0 to 1 ifthe critical study has attendant strengths.
The RfC considers the relationship between exposure concentration and dose delivered to the target site. The respiratory tract dosimetry of gases and particles differs across species, though similar respiratory tract regions are considered (9, 10) . The respiratory tract anatomy, physiology, xenobiotic metabolism, and biochemistry (mucous interaction) and the physicochemical properties of the inhaled toxicant account for differences in deposition across the species. Evaluation of dose-response curves across species requires knowing the dose delivered to the target tissue, and the target tissue dose is determined by absorption, distribution, metabolism, and excretion. The RfC process assumes that either absorption is equivalent across species or that the differences in absorption are so minimal that the interspecies uncertainty factor accounts for them along with other pharmacokinetic and pharmacodynamic differences. Use of physicochemical, physiological, anatomical, and biochemical adjustments will minimize the uncertainty of RfC development.
Because ofdosimetric differences between the experimental species and humans, NOAELs determined from experimental exposure levels in animals need to be adjusted to human equivalent concentrations (HEC). The calculation of HECs for the NOAEL requires several steps. Figure 1 shows 
Concentration Conversion
If exposure levels are expressed in units of parts per million, then the ideal gas law can be used to convert from parts per million to milligrams per cubic meter using Eq. where ppm = concentration expressed on a volumetric basis (L/106L), MW = molecular weight in grams, 22.4 L = the volume occupied by 1 g-mole of a gas at 0'C and, 760 mm Hg, T = actual temperature in degrees Kelvin, and P = actual pressure in mm Hg. Exposures may typically occur at 25°C rather than 0°C. The volume of 1 g-mole of perfect gas at 25°C is 24 .45 L, and the conversion is simplified to mg/m3 = ppm x MW/24.45.
Dose Duration Adjustment
A dose duration adjustment is necessary when developing RfCs because they are based on continuous exposure, and supporting experimental exposure regimens are likely to be discontinuous. Normalization of discontinuous exposure to lifetime continuous exposure is achieved by the following equation for the adjusted NOAEL (NOAELIADJl).
NOAELID(mg/m' = E(mg/m3) x D(hours/day/24 hours)
where E = experimental exposure level, D = number of (hr exposed/day)/24 hr, and W = number of(days ofexposure/week)/7 days.
Duration and solubility effects may affect the accuracy of the simple direct relationship expressed in Eq. (2) . Ideally, the exposure duration should include the period of time during which toxic effects sharply change (11) . Tissue concentrations of a gas also vary with lipid solubility. Gases with high blood-to-air partition coefficients are lipid soluble. First-order kinetics ofuptake and elimination are also assumed by Eq. (2).
Human Equivalent Concentrations
After the NOAEL is adjusted for duration of exposure, HECs for either particles or gases must be calculated. The respiratory anatomy, ventilation characteristics, and biochemical and metabolic reactions of the exposed species significantly influences the HEC of an inhaled particle or gas.
Anatomical and physiological differences in humans and animals affect air flow in the respiratory system. The three regions of the respiratory system, nasopharyngeal, tracheobronchial, and pulmonary, are characterized by different structure, size, and function, and the anatomy, physiology, and clearance mechanisms of these regions determine the retained dose ofparticles in the respective regions. The nasopharyngeal region, also referred to as the extrathoracic region, consists ofthe anterior nares and extends back and down to the level of the larynx. This region is characterized by a lining of vascular mucous epithelium. Filtration, humidity and temperature changes, and absorption of inhaled gases also occur in the nasopharyngeal region. The trachea, bronchi, and bronchioles are the conducting airways that compose the tracheobronchial region. The upper airways (trachea and bronchi) of this region are lined with a ciliated epithelium coated with a thin layer of mucus. The mucociliary escalator of the conducting airways clears particles from the deep lung to the oral cavity, and the mucus can react with or absorb gases, thereby changing the dose to the epithelium. The airway branching patterns and dimensions are critical in determining particle deposition and gas absorption. The pulmonary region consists of first-order respiratory bronchioles, alveolar duets, and alveolar sacs. This region is the primary site of gas exchange between the environment and the blood.
Particle Effects
The deposition of insoluble particles in various parts of the respiratory system are shown in Figure 2A for nasal inhalation and in Figure 2B for oral inhalation (12) . Particles greater than 2.5 Zm mass median aerodynamic diameter are deposited preferentially in the nasopharyngeal (extrathoracic) region. Compared to nasal inhalation, oral inhalation shifts the deposition ofparticles to higher fractions for both the tracheobronchial and pulmonary regions.
The HEC calculations for particles also rely on the physicochemical characteristics ofparticles and temperature and pressure conditions for gases. Physicochemical characteristics affect particle deposition and retention within the respiratory tract, translocation within the respiratory system, distribution to other tissues, and toxic effects. The sizes ofmost particles approximate a log-normal distribution. Assuming a log-normal function, the size of particles may be described by the mass median aero-Nasal Inhalation Deposition , HEC for Respiratory Effects from Particles Deposition efficiency and particle distribution information can be used to calculate the deposited dose of exposure particles when these particles exist as an insoluble aerosol. The deposited fraction for any region of the respiratory system is a function of deposition efficiency and particle mass fraction. Integration across all particle sizes will give the mass deposition in a particular region. Deposition in a particular region for a given species is obtained from the product ofthe fractional deposition, v ventilation rate, and exposure level divided by the regional surface area. Thus, assuming the equivalent dose across species is the aerosol mass deposited per regional surface area, the regional deposited dose (RDD) for the extrathoracic region is determined 100.00 as in Eq. (3). where Pi = the particulate mass fraction in the exposure size distribution (MMAD, org), E, = the deposition efficiency of that size distribution (MMAD, ag) in the extrathoracic region for the species of interest, i = size range, n = number of size ranges, Y = exposure level (mg/m3), VT = tidal volume (mL), f = breathing frequency (breaths/min), and SET = surface area of the extrathoracic region (cm2).
Deposition ofonly one size range (i) ofparticles for one region (extrathoracic) is shown in Eq. (3). Toxic effects in other regions necessitate use ofparameters defining the affected region. Summation over multiple (n) particle ranges and multiple regions (extrathoracic, tracheobronchial, pulmonary, thoracic, or total) is possible using the same expression and knowledge ofthe respective surface areas (S), particulate mass fractions (P), and deposition efficiency (E).
The RDD can be calculated for each species of interest using the same MMAD and a.. The regional deposited dose ratio (RDDR) is used to convert the adjusted NOAEL to the human equivalent concentration as follows:
NOAEL mEcl(mg/m3) = NOAELjADj(mg/m3) x RDDR (4) where NOAELIHECJ = the NOAEL human equivalent concentration, NOAELIADJJ = the NOAEL adjusted for duration according to Eq. (2), and RDDR = (RDDANIMAL)/(RDDHUMAN), the ratio of regional deposited dose in animal species to that of humans for the region and toxic effect of interest.
Because dosimetric data from rats are available, the RDDR of insoluble particles for rats to humans has been calculated for ag of 1.2, 1.4, 1.8,2.0,2.2, and 2.4 at MMAD of0.lOOto 10 .000 tm for an extrathoracic, tracheobronchial, pulmonary, thoracic, (tracheobronchial plus pulmonary), or total respiratory (extrathoracic plus thoracic) effect (4, 15) .
HEC for Extrarespiratory Effects of Particles
If the toxic effect of an inhaled particle is outside the respiratory tract, then the effect is extrarespiratory, and the equivalent dose across species is based on the particle mass deposition per body weight. In the absence of data indicating otherwise, 100% of the deposited dose is assumed available for systemic absorption and circulation. However, clearance and distribution data could alter this assumption. Eq. (5) 
(3).
The ratio ofthe animal RDD to the human RDD is used to convert the adjusted animal NOAEL to a NOAEL as a human equivalent concentration as in Eq. (6).
NOAELIHM(mg/m3) = NOAELlA (mg/m3) x RDDRER (6) where NOAELIHECI = the NOAEL human equivalent concentration, NOAELIADJI = the NOAEL adjusted for duration according to Eq. (2), and RDDER = (RDDER)A/(RDDER)H, the ratio ofthe dose available for uptake from the entire respiratory system of the experimental animal species to that of humans.
The RDDR for rats to humans for insoluble particles in a range of 1.2 to 2.0 ag and an MMAD of 0.100 to 10.000 ,um have been calculated for the extrarespiratory region (4,15). (8) where RGDR = (RGD)ANIMAL/(RGD)HUMAN, the ratio of regional gas dose in animal species to that of humans for the region and toxic effect of interest, and other variables are as defined in Eq. (6). Some gases may be highly soluble in the blood and yet have effects on lung tissue. The lung effect ofthese gases is indirect, and the dosimetry should be treated like the extrarespiratory effects for gases as described below.
Gas Effects

HEC for Extrarespiratory Effects of Gases
The approach to determine HECs for extrarespiratory effects of gas exposures should estimate NOAELIHECJ values as a function of the average animal exposure concentration, i.e., NOAELIADJI. Four methods for achieving these estimations have been studied (16) . The methods are referred to as proposed, established, similar, and optimal. The proposed method is a simple methodology for extrapolating dosimetry from rat studies to human. This method assumes the effective dose is the arterial blood concentration or its concentration multiplied by time and that the blood:air partition coefficient for the animal (XA) is less than or equal to the blood:air partition coefficient for the human (XH). The proposed method is more conservative, i.e., gives lower HECs, than other methods, including: a) the established method, which adjusts dosimetry simply on the basis ofventilation rate dividedby body weight; b) a method similar to the optimal model method, which uses human physiological parameters and animal parameters scaled from these; and c) the optimal method which uses physiologically based pharmacokinetic (PB-PK) model requiring a complete set of physiological parameters for animals and humans.
Physiologically based pharmacokinetic models may use five compartments, including gas exchange, fat, poorly perfused, richly perfused, and liver/metabolizing tissue groups to describe the body (17) . The relevant physiological and biochemical parameters and the agent's mechanism ofaction are needed to use the PB-PK model approach. However, these data are not available for most gases. The relationship of these methods is shown in Figure 3 (16) , which shows that the proposed method produces the most conservative NOAEL!HECI from the animal NOAEL. Because the blood:air partition coefficients are more readily available than are complete physiological parameter data, a ratio of animal to human blood:air partition coefficients is a simple, conservative default that closely approaches the optimal method.
If the concentration of gas in the arteries leaving the lung is periodic, then the blood:air partition coefficient will control the arterial concentration. Periodicity occurs when consistent and regular exposure to a gas is such that clearance from the blood is inadequate to remove the incremental gas concentration until exposure ceases. Once the exposure resumes, incremental increases in blood gas concentration resume as before. This process recurs at regular intervals. A study demonstrating periodicity is shown in Figure 4 (16 where (VA/BW)A/(VH/BW)H = the ratio of the alveolar ventilation rate (mL/min) divided by body weight (kg) of the animal species to the same parameters for humans, and other variables are as defined in Eq. (6). More uncertainty is associated with this method, and a modifying factor should be included. The alveolar ventilation rate should be used to eliminate error associated with the area ofthe lung that has no gas exchange with the blood.
Dose-Response Modeling
Dose-response modeling is a mathematical description relating exposure to changes (e.g., toxic effects) in a biological system. Dose-response models can use all available data, thereby predicting the toxic effect over a wide range of exposures. However, while yielding precise and reproducible predictions of risk, the mathematical nature of dose-response models can lead to overinterpretation.
Dose-response models should be selected based on the intent ofthe risk assessment. An empirical curve-fitting model should be used if the risk at a dose within the experimental range is desired, and a mechanistic model should be used to predict risk at a very low level below the range of data points. The quality and suitability of toxicity data must be evaluated in dose-response models. The data must be described by mathematical constructs. Any nonlinearity in data requires at least three data points (i.e., dose groups) to define the mathematical relationship. When Dose-intensity models use continuous measurements and assume that deviation from the normal value increases with increasing dose (18, 19) . The numerical value derived from these models is not an indication of hazard. Rather, the measured effect must be compared to control populations. The probability of an effect being adverse may be derived from these models if the probability distribution of normal measurements is derived first.
Dose-severity models are used when dealing with toxicity grouped in severity categories. These models should be used when the general severity of toxic response is the assessment goal. This 
Decision Analytic Approach
The decision analytic approach to dose-response relationships emphasizes the characterization and representation ofthe major uncertainties in the estimate. Probability is used to quantify the degree of uncertainty. These uncertainties arise because of measurement error, sample size, sampling protocol, and insufficient health effects data. The judgmental interpretation of probability is also known as Bayesian interpretation. The Bayesian viewpoint is that probabilities represent an individual's degree of belief about a given quantity rather than a measured property of the world (20) .
Decision analysis permits characterization of uncertainties in terms of probability often obtained by eliciting probabilistic judgments from scientific experts. Such an approach has been used for lead (5) and ozone (21) . The approach should be used when a distribution of risk estimates for a defined health end point associated with given levels and conditions of human exposure are desired. The decision analytic approach to doseresponse assessment is more data intensive than the RfC approach and often requires an ability to elicit expertjudgment and the cooperation ofthese experts. The scientific experts should be recognized, competent scientists who have done research and published in the area of interest. The experts should represent a range of credible scientific viewpoints.
This process begins with developing an assessment protocol that guides the collection of qualitative and quantitative judgments by ensuring that questions are phrased identically to all experts, that specific assumptions and definitions are common to all experts, and that the encoding process is carried out similarly with all participants. The appropriate health end point must be defined for the expert participants. Exposure conditions, populations of interest, and geographical areas of interest must also be defined for the experts as part of the encoding protocol (22) .
Probabilistic dose-response relationships are obtained from experts in an interview session. The process is referred to as "probability encoding." Initially, the purpose of the session is established followed by defining the unknown quantity for which judgment will be elicited. The scientific literature relevant to the relationships and possible biases are discussed. After this discussion, values that bound specific probability intervals are determined. Experts are asked to express judgments in probabilistic form. The encoding process establishes upper and lower bounds on plausible response rates at a specific exposure level, i.e, an upper response rate that would be exceeded with probability 0.01 and a lower response rate that would be exceeded with probability 0.99. The median response rate is also determined, which is a response rate such that the true response rate is equally likely to be above or below it. Probabilities for other response rates are also encoded. Encoded probabilities for several exposure levels can be plotted on a graph. Implications ofthe graph ofprobabilities are discussed and the experts allowed to make any changes (22) . These probability judgments are checked for stability and coherence, i.e., the judgments must satisfy the laws of probability such as additivity.
When an adequate database is available, a probabilistic doseresponse relationship and an estimate ofuncertainty can be obtained. However, since the assessment must be for humans and the population from which the data was drawn is likely to be from animals, extrapolation is required. Probabilistic dose-response relationships can be presented as curves on a graph ofdose or exposure versus response rate. The curves can consist of the 0.5, 0.05, and 0.95 fractile distributions. The 0.05 and 0.95 fractile distributions bound the 90% credible interval, i.e., 0.9 probability that the "true" dose-response relationship lies in the designated range. Each expert's 90% credible interval can then be compared to assess a total range for the 0.9 probability ofthe "true" doseresponse curve. Finally, the available information must be interpreted by scientific assessors. The information developed in the preceding steps on analogous substances and metabolites will likely be limited in some respects and therefore requirejudgment and integration. The data on analogues should be evaluated based on the similarity to the chemical under study, and metabolites should be evaluated based on their formation and toxicological significance. Parameters to be evaluated are dermal, pulmonary, and gastrointestinal absorption; distribution and excretion; and possible mechanisms of toxicity and the ability ofthe chemical and its analogues to operate by such mechanisms. The greater the similarity between the chemical in question and its analogues, the more reliable the hazard identification.
Summary
Risk assessments from exposure to indoor air pollutants require exposure assessments and dose-response assessments. Dose-response assessment methodologies have been discussed here. These methods include the inhalation reference concentration, structure-activity relationships, dose-response models, and the decision analytic approach. The RfC is an estimate (with uncertainty spanning perhaps an order of magnitude) ofa daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. The current RfC method provides guidelines for making the necessary dosimetric adjustments for gases and aerosols. Human equivalent concentrations for no-observed-adverse-effect levels in animals are determined by using mathematical relationships that adjust for regional deposition, solubility, ventilation rate, and blood:air partition coefficients. Physiologically based pharmacokinetic models can also be used in some cases to predict the human equivalent concentration more accurately. Dose-response modeling, although very data intensive, describes the doseresponse relationship over the entire range of data and can be modified to address different assessment goals. The decision analytic approach to dose-response assessment can be used to obtain a distribution of risk estimates for a defined health end point by using expertjudgment regarding the dose-response relationship. Structure-activity relationships may be used for hazard identification when few or no test data exist, and chemical analogues can be identified which have similar structural, metabolic, and toxic effects as the chemical of concern.
The RfC methodology exists as an interim methodology. Future scientific advancements are expected to further refine the approach. Quantitation and reduction ofuncertainty are the subject of current research designed to improve this dose-response methodology. In addition to the analysis of uncertainty for the RfC methodology, physiologically based pharmacokinetic models are being actively pursued for many chemicals. These models will reduce the uncertainty ofextrapolation from animals to humans. Research into route-to-route extrapolation will further expand the scope of the RfC procedure. Research into biologically based dose-response models and mixtures are other areas that will reduce uncertainty in dose-response models and, therefore, in indoor air risk assessments in the future.
